NCT05650697 (TOPSCAR) is a EARLY_PHASE1 clinical trial of Group 1 cannabidiol (CBD) with silicone ointment in Forehead; Wound, sponsored by University of Oklahoma.

Who is sponsoring NCT05650697?

NCT05650697 is sponsored by University of Oklahoma.

What drugs are being tested in NCT05650697?

Interventions in NCT05650697: Group 1 cannabidiol (CBD) with silicone ointment, Group 2 silicone patch.

What condition does NCT05650697 study?

NCT05650697 studies Forehead; Wound.

Is NCT05650697 still recruiting?

NCT05650697 is currently not yet recruiting. Last updated 26 March 2026.

Last reviewed 2026-03-26 · How we verify

NCT05650697: TOPSCAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Topical Cannabidiol on Paramedian Forehead Flap Scar Healing: A Split Scar Study

Not yet recruiting EARLY_PHASE1 Last updated 26 March 2026

What this trial tests

EARLY_PHASE1 trial testing Group 1 cannabidiol (CBD) with silicone ointment in Forehead; Wound in 22 participants. Not yet recruiting.

Timeline

1 September 2026

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	University of Oklahoma
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	22
Start date	1 September 2026
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	1 location across United States

Drugs / interventions tested

Group 1 cannabidiol (CBD) with silicone ointment — full drug profile →
Group 2 silicone patch — full drug profile →

Conditions studied

Forehead; Wound — all drugs for Forehead; Wound →

Sponsor

University of Oklahoma

Who can join

Adults 18 to 99, any sex, with Forehead; Wound. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Assessment of subjective and objective effects of CBD on the outcomes of healing scars
Time frame: 2 years
Proportion of patients who have a positive effect using CBD oil in combination with the silicone patch. This will be assessed using the Scar Cosmesis Assessment and Rating (SCAR) scale to determine the impact of CBD oil and silicon patch combo. This photographic evaluation of scare will be done over a period of around 7 months to evaluate the scar outcomes, using the scoring system with minimum sc

Sponsor's own description

The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Strategies to Improve Cannabidiol Bioavailability and Drug Delivery.
O'Sullivan SE, Jensen SS, Kolli AR, Nikolajsen GN, et al · · 2024 · cited 23× · PMID 38399459 · DOI 10.3390/ph17020244
The Potential Role of Cannabidiol in Cosmetic Dermatology: A Literature Review.
Kuzumi A, Yoshizaki-Ogawa A, Fukasawa T, Sato S, et al · · 2024 · cited 10× · PMID 39369127 · DOI 10.1007/s40257-024-00891-y
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.
Rusu A, Farcaș AM, Oancea OL, Tanase C. · · 2025 · cited 2× · PMID 41008526 · DOI 10.3390/biom15091219

Verify or expand the search:

Other University of Oklahoma trials

Trials by the same sponsor.

NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05650697 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
Last refreshed: 26 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05650697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing